Ki-back W. Chu

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Dose- and time-dependent dissemination of viable Leishmania amazonensis following experimental footpad infection in mice.

Dose- and time-dependent dissemination of viable Leishmania amazonensis following experimental footpad infection in mice.

Journal: Acta tropica

Published: April 03, 2026

Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain.

Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain.

Journal: Nanomedicine (London, England)

Published: February 23, 2024

Virus-Like Particles Assembled Using Respiratory Syncytial Virus Matrix Protein Elicit Protective Immunity in Mice.

Virus-Like Particles Assembled Using Respiratory Syncytial Virus Matrix Protein Elicit Protective Immunity in Mice.

Journal: Infection and drug resistance

Published: July 13, 2023

The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques.

The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques.

Journal: Parasites, hosts and diseases

Published: April 14, 2023

Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.

Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.

Journal: Pharmaceutics

Published: January 21, 2023

Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

Journal: Viruses

Published: December 12, 2022

Recombinant Vaccinia Virus Expressing Plasmodium berghei Apical Membrane Antigen 1 or Microneme Protein Enhances Protection against P. berghei Infection in Mice.

Recombinant Vaccinia Virus Expressing Plasmodium berghei Apical Membrane Antigen 1 or Microneme Protein Enhances Protection against P. berghei Infection in Mice.

Journal: Tropical medicine and infectious disease

Published: October 05, 2022

Virus-like particles coexpressing the PreF and Gt antigens of respiratory syncytial virus confer protection in mice.

Virus-like particles coexpressing the PreF and Gt antigens of respiratory syncytial virus confer protection in mice.

Journal: Nanomedicine (London, England)

Published: September 14, 2022

Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles Expressing Toxoplasma gondii Rhoptry Protein 18.

Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles Expressing Toxoplasma gondii Rhoptry Protein 18.

Journal: Vaccines

Published: August 19, 2022

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.

Journal: Parasites, hosts and diseases

Published: August 15, 2022

Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 of Plasmodium berghei.

Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 of Plasmodium berghei.

Journal: Biomedicines

Published: August 05, 2022

Recombinant AMA1 Virus-like Particle Antigen for Serodiagnosis of Toxoplasma gondii Infection.

Recombinant AMA1 Virus-like Particle Antigen for Serodiagnosis of Toxoplasma gondii Infection.

Journal: Biomedicines

Published: August 04, 2022

Showing 1-12 of 66

Last Updated: 09/26/2026